

Andrew M Tonkin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/139217/andrew-m-tonkin-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

4,911
citations

30
h-index

69
g-index

146
ext. papers

6,424
ext. citations

7.8
avg. IF

4.95
L-index

#	Paper	IF	Citations
109	Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial.. <i>The Lancet Healthy Longevity</i> , 2022 , 3, e109-e118	9.5	2
108	A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data.. <i>The Lancet Healthy Longevity</i> , 2022 , 3, e89-e97	9.5	2
107	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.. <i>Journal of the American Heart Association</i> , 2022 , e020745	6	3
106	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial.. <i>Atherosclerosis</i> , 2022 , 346, 68-74	3.1	
105	Trajectories of depressive symptoms in older adults and associated health outcomes. <i>Nature Aging</i> , 2022 , 2, 295-302		1
104	Cardiovascular risk prediction in healthy older people. <i>GeroScience</i> , 2021 , 1	8.9	1
103	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2021 , 1	2.8	2
102	Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3145-3156	15.1	1
101	Genetic variants associated with inherited cardiovascular disorders among 13,131 asymptomatic older adults of European descent. <i>Npj Genomic Medicine</i> , 2021 , 6, 51	6.2	3
100	Role of Cardiac Biomarkers in Epidemiology and Risk Outcomes. <i>Clinical Chemistry</i> , 2021 , 67, 96-106	5.5	3
99	Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. <i>Kidney International</i> , 2021 , 99, 466-474	9.9	5
98	Long-Term Blood Pressure Variability and Risk of Cognitive Decline and Dementia Among Older Adults. <i>Journal of the American Heart Association</i> , 2021 , 10, e019613	6	4
97	Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021 , 337, 9-15	3.2	0
96	Predictive Performance of a Polygenic Risk Score for Incident Ischemic Stroke in a Healthy Older Population. <i>Stroke</i> , 2021 , 52, 2882-2891	6.7	3
95	Health-related quality of life and incident cardiovascular disease events in community-dwelling older people: A prospective cohort study. <i>International Journal of Cardiology</i> , 2021 , 339, 170-178	3.2	2
94	Effect of Atorvastatin on Knee Cartilage Volume in Patients With Symptomatic Knee Osteoarthritis: Results From a Randomized Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2035-2043	9.5	1
93	Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.. <i>Circulation Genomic and Precision Medicine</i> , 2021 , CIRCGEN121003429	5.2	0

92	Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality.. <i>BMC Geriatrics</i> , 2021 , 21, 711	4.1	9
91	Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. <i>European Heart Journal</i> , 2020 , 41, 371-380	9.5	87
90	Impact of the 2017 American Heart Association and American College of Cardiology hypertension guideline in aged individuals. <i>Journal of Hypertension</i> , 2020 , 38, 2527-2536	1.9	0
89	Long-Term Blood Pressure Variability and Risk of Cardiovascular Disease Events Among Community-Dwelling Elderly. <i>Hypertension</i> , 2020 , 76, 1945-1952	8.5	11
88	Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 1834-1841	5.6	16
87	Familial Hypercholesterolemia in a Healthy Elderly Population. <i>Circulation Genomic and Precision Medicine</i> , 2020 , 13, e002938	5.2	2
86	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 17-27	15.1	9
85	Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1289-1298	6.1	5
84	Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals. <i>Genetics in Medicine</i> , 2020 , 22, 1883-1886	8.1	10
83	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study. <i>PLoS ONE</i> , 2020 , 15, e0228173	3.7	6
82	The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. <i>Journal of Human Hypertension</i> , 2020 , 34, 787-794	2.6	17
81	Factors Associated With Treatment and Control of Hypertension in a Healthy Elderly Population Free of Cardiovascular Disease: A Cross-sectional Study. <i>American Journal of Hypertension</i> , 2020 , 33, 350-361	2.3	2
80	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320938272	3.9	15
79	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
78	Vascular Pathology and Osteoarthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020 , 47, 748-760	4.1	9
77	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study 2020 , 15, e0228173		
76	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study 2020 , 15, e0228173		
75	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study 2020 , 15, e0228173		

74	Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort study 2020 , 15, e0228173		
73	The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2019 , 285, 1-5	3.2	9
72	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
71	Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. <i>CNS Drugs</i> , 2019 , 33, 685-694	6.7	6
70	Response by Simes et al to Letter Regarding Article, "D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease". <i>Circulation</i> , 2019 , 139, 1245-1246	16.7	
69	Evaluating recruitment strategies for AUSPICE, a large Australian community-based randomised controlled trial. <i>Medical Journal of Australia</i> , 2019 , 210, 409-415	4	7
68	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
67	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. <i>Heart Lung and Circulation</i> , 2019 , 28, 1018-1026	1.8	
66	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2019 , 105, 42-48	5.1	22
65	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 858-868	3.9	10
64	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 57-64	3.9	1
63	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged 65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 798-805	6.4	30
62	D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study. <i>Circulation</i> , 2018 , 138, 712-723	16.7	64
61	Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 37-46	3.9	3
60	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 813-819	6.4	48
59	LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 235-238	6.1	5
58	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018 , 392, 1311-1320	40	208
57	Effect of Aspirin on Disability-free Survival in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018 , 379, 1499-1508	59.2	224

56	Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018 , 379, 1519-1528	59.2	370
55	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. <i>New England Journal of Medicine</i> , 2018 , 379, 1509-1518	59.2	474
54	The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective. <i>International Journal of Cardiology</i> , 2018 , 267, 183-187	3.2	19
53	Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective. <i>International Journal of Cardiology</i> , 2018 , 270, 54-59	3.2	14
52	Baseline Characteristics of Participants in the ASPREE (ASpirin in Reducing Events in the Elderly) Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017 , 72, 1586-1593	6.4	92
51	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035	3.8	97
50	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
49	Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction model. <i>International Journal of Cardiology</i> , 2017 , 248, 361-368	3.2	10
48	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017 , 103, 1860-1866	5.1	39
47	Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 17	2.3	7
46	Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. <i>International Journal for Equity in Health</i> , 2017 , 16, 108	4.6	4
45	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. <i>Kidney and Blood Pressure Research</i> , 2017 , 42, 1033-1044	3.1	5
44	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017 , 6, e39	2	3
43	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016 , 134, 1637-1650	16.7	133
42	Polypharmacy in heart failure - Is reducing medication safe?. <i>International Journal of Cardiology</i> , 2016 , 214, 529-30	3.2	4
41	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 1393-400	3.9	12
40	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. <i>BMC Infectious Diseases</i> , 2016 , 16, 114	4	10
39	The BBlocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016 , 67, 902-11	7.4	26

38	Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). <i>American Heart Journal</i> , 2016 , 177, 58-65	4.9	29
37	Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. <i>Journal of Cardiac Failure</i> , 2016 , 22, 743-4	3.3	4
36	The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. <i>Heart Failure Reviews</i> , 2016 , 21, 675-697	5	30
35	Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy--a randomized controlled trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, 779-81	3.3	4
34	Comparison of anthropometric measures as predictors of cancer incidence: A pooled collaborative analysis of 11 Australian cohorts. <i>International Journal of Cancer</i> , 2015 , 137, 1699-708	7.5	35
33	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015 , 201, 499-507	3.2	36
32	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 920-30	3.9	98
31	Does statin use have a disease modifying effect in symptomatic knee osteoarthritis? Study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 584	2.8	15
30	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. <i>Cardiovascular Therapeutics</i> , 2015 , 33, 347-52	3.3	20
29	Impact of Fine Particulate Matter (PM2.5) Exposure During Wildfires on Cardiovascular Health Outcomes. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	124
28	Prediction of cardiovascular and all-cause mortality at 10 years in the hypertensive aged population. <i>American Journal of Hypertension</i> , 2015 , 28, 649-56	2.3	14
27	Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 315-24	15.1	46
26	Treatment of dyslipidemia. <i>F1000prime Reports</i> , 2014 , 6, 17		7
25	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , 2014 , 201, 671-3	4	12
24	Statins in the elderly: an answered question?. <i>Current Opinion in Cardiology</i> , 2014 , 29, 372-80	2.1	9
23	Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. <i>Journal of Cardiac Failure</i> , 2014 , 20, 522-32	3.3	28
22	Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. <i>International Journal of Cardiology</i> , 2014 , 172, 411-8	3.2	15
21	Reversing social disadvantage in secondary prevention of coronary heart disease. <i>International Journal of Cardiology</i> , 2014 , 171, 346-50	3.2	8

20	Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 2902-8	9.4	82
19	Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. <i>Journal of the American Heart Association</i> , 2013 , 2, e000360	6	38
18	Into the future: diversifying lipid management. <i>Lancet, The</i> , 2012 , 380, 1971-4	40	6
17	Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>American Heart Journal</i> , 2012 , 163, 508-14	4.9	23
16	A Pilot Study of Effects of Fruit Intake on Cardiovascular Risk Factors in Children. <i>ICAN: Infant, Child, & Adolescent Nutrition</i> , 2012 , 4, 348-354		1
15	AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. <i>Medical Journal of Australia</i> , 2010 , 192, 197-202	4	188
14	Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <i>Circulation</i> , 2010 , 122, 850-2	16.7	32
13	Where on the healthcare continuum should we invest? The case for primary care?. <i>Heart Lung and Circulation</i> , 2009 , 18, 108-13	1.8	4
12	Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?. <i>Medical Journal of Australia</i> , 2009 , 191, 356-357	4	1
11	Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. <i>American Heart Journal</i> , 2006 , 151, 1305-12	4.9	19
10	White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. <i>Circulation</i> , 2005 , 111, 1756-62	16.7	54
9	The metabolic syndrome(s)?. <i>Current Atherosclerosis Reports</i> , 2004 , 6, 165-6	6	3
8	Risk prediction: increasingly important, but questions still remain. <i>Current Atherosclerosis Reports</i> , 2003 , 5, 1-2	6	1
7	Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. <i>Australian and New Zealand Journal of Public Health</i> , 2003 , 27, 649-53	2.3	98
6	Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. <i>Circulation</i> , 2002 , 105, 1424-8	16.7	148
5	The need for medicine-based evidence as well as evidence-based medicine. <i>Current Atherosclerosis Reports</i> , 2001 , 3, 97-8	6	
4	Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 56-63	15.1	96
3	Susceptibility to atrial fibrillation: a study in an ovine model of pacing-induced early heart failure. <i>Journal of Cardiovascular Electrophysiology</i> , 1998 , 9, 423-35	2.7	46

- 2 Validation of an echocardiographic assessment of cardiac function following moderate size myocardial infarction in the rat. *Clinical and Experimental Pharmacology and Physiology*, **1996**, 23, 570-2 3 27
- 1 Adverse effects of low-dose aspirin in a healthy elderly population. *Clinical Pharmacology and Therapeutics*, **1993**, 54, 84-9 6.1 97